$47.82
1.64% yesterday
Nasdaq, Aug 27, 10:16 pm CET
ISIN
US05370A1088
Symbol
RNA

Avidity Biosciences Inc Target price 2025 - Analyst rating & recommendation

Avidity Biosciences Inc Classifications & Recommendation:

Buy
95%
Hold
5%

Avidity Biosciences Inc Price Target

Target Price $66.30
Price $47.82
Potential
Number of Estimates 19
19 Analysts have issued a price target Avidity Biosciences Inc 2026 . The average Avidity Biosciences Inc target price is $66.30. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 22 analysts: 21 Analysts recommend Avidity Biosciences Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of . Most analysts recommend the Avidity Biosciences Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 10.90 9.11
14.02% 16.39%
EBITDA Margin -3,451.01% -6,137.53%
41.29% 77.85%
Net Margin -2,956.88% -6,016.56%
33.20% 103.48%

17 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is

$9.1m
Unlock
. This is
15.07% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$13.8m 28.57%
Unlock
, the lowest is
$1.6m 85.39%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $10.9m 14.02%
2025
$9.1m 16.39%
Unlock
2026
$19.2m 110.16%
Unlock
2027
$328m 1,611.62%
Unlock
2028
$777m 136.96%
Unlock
2029
$1.3b 68.13%
Unlock
2030
$1.9b 46.78%
Unlock
2031
$2.5b 30.78%
Unlock
2032
$3.0b 18.95%
Unlock

6 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is

$-559m
Unlock
. This is
7.82% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-541m 4.34%
Unlock
, the lowest is
$-636m 22.61%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-376m 61.10%
2025
$-559m 48.69%
Unlock
2026
$-642m 14.86%
Unlock
2027
$-354m 44.97%
Unlock

EBITDA Margin

2024 -3,451.01% 41.29%
2025
-6,137.53% 77.85%
Unlock
2026
-3,354.37% 45.35%
Unlock
2027
-107.84% 96.79%
Unlock

18 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is

$-548m
Unlock
. This is
20.31% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-422m 7.34%
Unlock
, the lowest is
$-741m 62.58%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-322m 51.87%
2025
$-548m 70.12%
Unlock
2026
$-616m 12.31%
Unlock
2027
$-347m 43.57%
Unlock
2028
$-72.1m 79.24%
Unlock
2029
$322m 546.13%
Unlock
2030
$652m 102.47%
Unlock
2031
$969m 48.70%
Unlock
2032
$1.2b 20.39%
Unlock

Net Margin

2024 -2,956.88% 33.20%
2025
-6,016.56% 103.48%
Unlock
2026
-3,215.10% 46.56%
Unlock
2027
-106.00% 96.70%
Unlock
2028
-9.29% 91.24%
Unlock
2029
24.64% 365.23%
Unlock
2030
33.99% 37.95%
Unlock
2031
38.65% 13.71%
Unlock
2032
39.12% 1.22%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.89 -4.54
0.69% 57.09%
P/E negative
EV/Sales 545.27

18 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is

$-4.54
Unlock
. This is
29.34% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.50 0.28%
Unlock
, the lowest is
$-6.13 74.64%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.89 0.69%
2025
$-4.54 57.09%
Unlock
2026
$-5.10 12.33%
Unlock
2027
$-2.88 43.53%
Unlock
2028
$-0.60 79.17%
Unlock
2029
$2.66 543.33%
Unlock
2030
$5.40 103.01%
Unlock
2031
$8.02 48.52%
Unlock
2032
$9.66 20.45%
Unlock

P/E ratio

Current -13.62 26.12%
2025
-10.53 22.71%
Unlock
2026
-9.38 10.92%
Unlock
2027
-16.62 77.19%
Unlock
2028
-80.06 381.71%
Unlock
2029
17.95 122.42%
Unlock
2030
8.86 50.64%
Unlock
2031
5.96 32.73%
Unlock
2032
4.95 16.95%
Unlock

Based on analysts' sales estimates for 2025, the Avidity Biosciences Inc stock is valued at an EV/Sales of

545.27
Unlock
and an P/S ratio of
675.10
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 463.10 28.42%
2025
545.27 17.74%
Unlock
2026
259.45 52.42%
Unlock
2027
15.16 94.16%
Unlock
2028
6.40 57.80%
Unlock
2029
3.80 40.52%
Unlock
2030
2.59 31.87%
Unlock
2031
1.98 23.53%
Unlock
2032
1.67 15.93%
Unlock

P/S ratio

Current 573.36 18.67%
2025
675.10 17.74%
Unlock
2026
321.23 52.42%
Unlock
2027
18.77 94.16%
Unlock
2028
7.92 57.80%
Unlock
2029
4.71 40.52%
Unlock
2030
3.21 31.87%
Unlock
2031
2.45 23.53%
Unlock
2032
2.06 15.93%
Unlock

Current Avidity Biosciences Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
Locked
Locked Aug 08 2025
Barclays
Locked
Locked
Locked Aug 08 2025
Chardan Capital
Locked
Locked
Locked Aug 08 2025
Goldman Sachs
Locked
Locked
Locked Jul 10 2025
Cantor Fitzgerald
Locked
Locked
Locked Jun 27 2025
Wolfe Research
Locked
Locked
Locked Jun 17 2025
Raymond James
Locked
Locked
Locked Jun 11 2025
Analyst Rating Date
Locked
Wells Fargo:
Locked
Locked
Aug 08 2025
Locked
Barclays:
Locked
Locked
Aug 08 2025
Locked
Chardan Capital:
Locked
Locked
Aug 08 2025
Locked
Goldman Sachs:
Locked
Locked
Jul 10 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jun 27 2025
Locked
Wolfe Research:
Locked
Locked
Jun 17 2025
Locked
Raymond James:
Locked
Locked
Jun 11 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today